Introduction
============

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, which arises from the malignant transformation of lymphocyte progenitor cells to leukemic cells in the B- and T-cell lineages. B-cell precursor ALL (BCP-ALL) is the most common immunophenotype, which is divided into genetic subtypes with therapeutic and prognostic importance based on recurrent large-scale chromosomal aberrations that are detected in about 75% of the patients. Hyperdiploidy and t(12;21)*ETV6-RUNX1* (MIM\#s 600618, 151385) rearrangement characterize the most common subtypes, which are associated with a favorable outcome (Pui et al., [@b42]). The high-risk T-cell immunophenotype represents about 12% of the patients.

Genomic characterization of T-ALL, BCP-ALL samples carrying the t(12;21) rearrangement, and several of the high-risk BCP-ALL subtypes using microarrays and next generation sequencing has revealed distinct patterns of genetic lesions in these subtypes \[Mullighan, [@b37]; Papaemmanuil et al., [@b40]\], whereas few studies have addressed the genetics of BCP-ALL patients without a known primary genetic aberration. The focus of most studies has been on protein-coding regions, where the lesions have been found to affect hematopoietic development, cell cycle regulation, Ras and tyrosine signaling, cytokine receptors, tumor suppression, and epigenetic regulation \[Mullighan, [@b37]\]. The findings that most driver genes in acute myeloid leukemia are involved in gene regulation \[The Cancer Genome Atlas Research Network, [@b48]\], and that the *TERT* promoter is recurrently mutated across several types of human cancer \[Vinagre et al., [@b56]\] suggest that variants in non-coding regulatory regions might be more important for cancer development than recognized to date.

To determine the full range of genetic lesions in pediatric ALL, we sequenced the whole genomes and transcriptomes of two patients belonging to well-characterized groups (t(12;21) and T-ALL) and two patients without a known primary genetic aberration. We analyzed coding and non-coding regions of the genome and identified putative driver genes by targeted sequencing in 168 additional patients.

Materials and Methods
=====================

Patient Samples
---------------

The pediatric ALL patients analyzed in this study were diagnosed and treated at Swedish centers (Uppsala, Umeå, Stockholm and Gothenburg) according to the Nordic Society for Pediatric Haematology and Oncology (NOPHO) protocols \[Schmiegelow et al., [@b44]\]. ALL diagnosis was established by analysis of leukemic cells with respect to morphology, immunophenotype, and cytogenetics. ALL lineage (BCP-ALL or T-ALL) was defined according to the European Group for the Immunological Characterization of Leukemias. Fluorescence *in situ* hybridization (FISH) or reverse transcriptase PCR (RT-PCR) analyses were used to screen for gene fusions. Karyotypes were based on the International System for Human Cytogenetic Nomenclature \[Shaffer et al., [@b45]\]. Bone marrow aspirates collected at diagnosis of ALL and matched germline peripheral blood or bone marrow samples collected in first continuous complete remission (CCR1) from four patients were subjected to whole genome sequencing (WGS) (Table [1](#tbl1){ref-type="table"}). Targeted sequencing of 168 additional samples collected at ALL diagnosis and 159 matched CCR1 samples from the same patients was performed (Table [2](#tbl2){ref-type="table"} and Supp. [Table S1](#SD1){ref-type="supplementary-material"}). For nine patients, no CCR1 sample was available. An in-house RNA-seq dataset containing 27 BCP-ALL samples and 18 T-ALL samples (Nordlund, Dahlberg et al., unpublished data, Supp. [Table S2](#SD1){ref-type="supplementary-material"}) was used as control to assess potential effects of somatic variants on gene expression. This dataset provides a better control than matched remission samples, which are comprised of a mixture of mononuclear cells (T-cells, B-cells, monocytes, etc.) and therefore are expected to display substantial expression differences compared with ALL cells that are unrelated to somatic variants. The study was approved by the Regional Ethical Review Board in Uppsala, Sweden. The study was conducted according to the guidelines of the Declaration of Helsinki, and all patients and/or guardians provided written informed consent.

###### 

Clinical Characteristics of Whole Genome Sequenced ALL Patients

  Patient   Sex      Age[a](#tf1-1){ref-type="table-fn"}   WBC[b](#tf1-2){ref-type="table-fn"}   \% Blasts   Immunophenotype   Genetic subtype[c](#tf1-3){ref-type="table-fn"}   Treatment group[d](#tf1-4){ref-type="table-fn"}   Clinical follow-up[e](#tf1-5){ref-type="table-fn"}   Remission tissue
  --------- -------- ------------------------------------- ------------------------------------- ----------- ----------------- ------------------------------------------------- ------------------------------------------------- ---------------------------------------------------- ------------------
  ALL_458   Male     3.6                                   12.3                                  90          BCP-ALL           t(12;21)                                          IR                                                CCR1 (8.5)                                           PB
  ALL_559   Male     5.9                                   128.0                                 95          T-ALL             T-ALL                                             HR                                                CCR1 (7)                                             PB
  ALL_707   Male     1.6                                   9.6                                   80--90      BCP-ALL           Other                                             SR                                                CCR1 (5)                                             PB
  ALL_501   Female   6.7                                   1.4                                   80          BCP-ALL           Normal                                            SR                                                CCR1 (8)                                             BM

Age at diagnosis in years.

White blood cell count at diagnosis (10^9^ cells/l).

The full karyotypes are:

ALL_458: 46,XY.ish.t(12;21)(p13;q22),del(12)(p13p13),del(21)(q22q22)

ALL_559: 46,XY,t(7;9)(q3?4;q3?2)\[10\].ish.del(9)(p21p21)x2,der(11)t(7;11)(q3?4;p1?3)/46,XY\[15\]. The t(7;9) was detected by G-banding in 10 of 25 metaphases. Remaining aberrations, and t(7;9), were detected by FISH. The question marks indicate that the breakpoint on sub-band level is uncertain.

ALL_707: 46,XY,der(7)t(7;9)(q11;p13)del(9)(p21p24),der(9)t(7;9)(q11;p13),del(19)(q13)\[24\]/46,XY\[1\]

ALL_501: 46,XX\[20\]. Hyperdiploidy and the most common rearrangements (*BCR-ABL1*, *PBX1-TCF3*, *ETV6-RUNX1*, and *MLL*) were excluded by FISH and DNA index analysis.

The patients were treated according to the Nordic Society for Pediatric Haematology and Oncology (NOPHO) protocols \[Schmiegelow et al., [@b44]\].

Within parenthesis is the follow-up time in years.

BCP-ALL, B-cell precursor ALL; SR, standard risk; IR, intermediate risk; HR, high risk; CCR1, first continuous complete remission; PB, peripheral blood; BM, bone marrow.

###### 

Cytogenetic Representation of ALL Patients Included in the Validation Cohort

  Immunophenotype   Genetic subtype[a](#tf2-1){ref-type="table-fn"}   Number of patients[b](#tf2-2){ref-type="table-fn"}   Population (%)[c](#tf2-3){ref-type="table-fn"}
  ----------------- ------------------------------------------------- ---------------------------------------------------- ------------------------------------------------
  BCP-ALL           HeH                                               47 (28.0)                                            26.3
                    t(12;21)                                          35 (20.8)                                            16.7
                    Other                                             21 (12.5)                                            13.4
                    Normal / no result                                18 (10.7)                                            21.7
                    t(9;22)                                           8 (4.8)                                              2.2
                    11q23/MLL                                         4 (2.4)                                              3.6
                    iAMP21                                            4 (2.4)                                              0.5
                    t(1;19)                                           4 (2.4)                                              1.9
                    dic(9;20)                                         3 (1.8)                                              1.8
                    \> 67 chr                                         1 (0.6)                                              0.4
  T-ALL             T-ALL                                             23 (13.7)                                            10.5
  Total                                                               168 (100)                                            99.0

HeH, high hyperdiploidy (51--67 chromosomes); t(12;21), translocation between the chromosomes (12;21)(p13;q22)*ETV6-RUNX1*; t(9;22), translocation between the chromosomes (9;22)(q11;q34)*BCR-ABL1*; 11q23/MLL, translocation between *MLL* and various other genes; iAMP21, intrachromosomal amplification of chromosome 21; dic(9;20), dicentric chromosome (9;20)(p13;q11); \> 67 chr, \> 67 chromosomes; Other, other clonal aberrations; Normal, no genetic aberrations detected and a normal karyotype observed in at least 5 of 25 metaphases; No result, no karyotype reported or the cytogenetic analysis failed.

Within parenthesis is the percentage of samples of each subtype in the validation cohort.

Percentage of each subtype in 2367 patients diagnosed with ALL in the Nordic countries during 1996--2008. The frequency of subtypes changes with time, since new subtypes are discovered and new analysis methods are added. The reason why the population does not sum to 100% is that the rare subtype hypodiploidy is not represented in the validation cohort.

Mononuclear cells were isolated with 1.077 g/ml Ficoll-Isopage (Pharmacia, Uppsala, Sweden) density-gradient centrifugation. The proportion of leukemic cells was estimated to be ≥80% in all samples by light microscopy in May-Grünwald-Giemsa-stained cytocentrifugate preparations. DNA and RNA were extracted from vital frozen cells or cell pellets containing 1--15 million cells using the QIAamp DNA Blood or AllPrep DNA/RNA Mini Kit (Qiagen, GmbH, Hilden, Germany). RNA samples were treated with DNase using the RNase-Free DNase Set (Qiagen). DNA and RNA were quantified using the Qubit dsDNA Broad-Range assay and Qubit RNA Broad-Range assay, respectively, on a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA). The integrity of the RNA was examined by capillary electrophoresis with a Bioanalyzer using RNA 6000 Nano Labchips (Agilent, Technologies, Santa Clara, CA, USA).

WGS and Analysis of WGS Data
----------------------------

Four to eight WGS libraries were prepared from diagnostic and remission DNA from each of the four selected ALL patients. The libraries were sequenced paired-end with 100 or 150 bp reads using a HiSeq2000 or GAIIx instrument (Illumina Inc, San Diego, CA, USA). Sequence reads were aligned to the human reference genome hg19 using BWA \[Li and Durbin, [@b25]\]. Single nucleotide variants (SNVs) were called with SomaticSniper \[Larson et al., [@b22]\] and insertion-deletions (indels) were called with GATK \[DePristo et al., [@b9]\]. A variant was considered conserved if it overlapped a conserved non-exonic element (CNEE) \[Lowe et al., [@b29]\] or a region present in the phastCons track from the UCSC table browser. DNase hypersensitive (DHS) regions and active histone marks (H3K4me1, H3K27ac, H3K4me3, H3K36me3) in lymphoid cells were determined using data from the NIH Epigenomics project \[Bernstein et al., [@b5]\] as previously described \[Nordlund et al., [@b39]\]. The experiment IDs are listed in Supp. [Table S3](#SD1){ref-type="supplementary-material"}. Somatic copy number alterations (CNAs) were called using BIC-Seq \[Xi et al., [@b60]\], ControlFREEC \[Boeva et al., [@b6]\], dwac-seq (<https://github.com/Vityay/DWAC-Seq>), and Patchwork \[Mayrhofer et al., [@b33]\]. CNAs detected by at least two programs were retained. All variants were annotated against the Ensembl database.

RNA Sequencing and Analysis of RNA Sequence Data
------------------------------------------------

Strand-specific libraries for RNA-sequencing (RNA-seq) were prepared from 1 μg RNA using the ScriptSeq V2 RNA-seq Library Preparation Kit (Epicentre, Madison, WI, USA) after ribosomal RNA depletion with the Ribo-Zero method (Epicentre). Paired-end sequencing was performed on a HiSeq2000/2500 (Illumina). The read length was 100 bp for the four whole genome sequenced samples and 50 bp for the samples in the control dataset. Alignment of sequence reads and quantification of expression levels was performed with TopHat and Cufflinks \[Trapnell et al., [@b50]\]. The expression levels were normalized to fragments per kilobase per million mapped reads (FPKM) with Cufflinks. Fusion genes were identified using FusionCatcher (Nicorici et al., submitted manuscript).

HumanOmni2.5 BeadChip Genotyping
--------------------------------

Two hundred and fifty nanograms of DNA from diagnostic and remission samples from the four whole genome sequenced patients was genotyped using the HumanOmni2.5 BeadChip (Illumina). The diploid coverage of the WGS data was estimated as the percentage of heterozygous sites detected using genotyping that were also heterozygous in the sequence data. CNAs were predicted using ASCAT \[Van Loo et al., [@b53]\].

Target Capture Experiment
-------------------------

The following categories of genomic regions were selected for target capture and resequencing (Supp. [Fig. S1](#SD1){ref-type="supplementary-material"}): (1) 51 bp regions flanking all candidate SNVs identified by WGS. (2) Exons of genes with an SNV or indel in an exon or an untranslated region (UTR) (Supp. [Table S4](#SD1){ref-type="supplementary-material"}). (3) Non-coding conserved or DHS regions containing a candidate SNV and regions flanking candidate SNVs with score ≤2 in RegulomeDB \[Boyle et al., [@b8]\]. Target capture was performed using 200 ng DNA and reagents from a HaloPlex Target Enrichment kit (Agilent), according to the HaloPlex Target Enrichment System Automation Protocol Version D.3. All leukemic samples (*n* = 172) and the four whole genome sequenced remission samples were enriched individually. Remaining remission samples were enriched in pools of 10 samples. In addition, 84 samples from healthy Swedish blood donors, enriched in pools of 21 samples, were included as population controls. Paired-end sequencing with read length of 100 bp was performed on a HiSeq2000/2500 (Illumina). The average sequence depth in the target region was 638× for ALL samples in the validation cohort, 162× for remission samples, and 133× for Swedish blood donors (Supp. [Fig. S2](#SD1){ref-type="supplementary-material"}).

Validation of Somatic Variants Identified by WGS
------------------------------------------------

Exonic indels (*n* = 2 of 6 tested) and a subset of candidate SNVs (*n* = 50 of 60 tested) identified by WGS were validated by PCR and Sanger sequencing. Fifty nanograms of genomic DNA was whole genome amplified using the REPLI-g Midi Kit (Qiagen). PCR primers were designed using Primer3Plus \[Untergasser et al., [@b52]\]. ALL and remission samples were amplified by PCR and the products were sequenced with BigDye Terminator 3.1 chemistry using an Applied Biosystems 3730XL DNA sequencer. The sequence traces were analyzed with the Sequencher software (Applied Biosystems, Foster City, CA, USA). For validation of remaining SNVs, the allele fraction (AF) from the target capture experiment was calculated with a custom Python script (available at <https://github.com/Molmed/Berglund-Lindqvist-2013>). A candidate SNV was considered validated if the AF was ≥ 0.1 in the ALL sample, the AF was \< 0.01 in the matched remission sample, and the sequence depth was ≥10 in both samples. Bases with a Phred quality score \< 20 and bases in a read with mapping quality = 0 were disregarded. Positions where an SNV was called in more than one patient were manually inspected in the Integrative Genomics Viewer \[Thorvaldsdottir et al., [@b49]\].

Variant Calling in the Validation Cohort
----------------------------------------

SNVs and indels in the validation cohort were called with FreeBayes (<http://arxiv.org/abs/1207.3907>) and the GATK HaplotypeCaller \[DePristo et al., [@b9]\], respectively. Variants were filtered based on sequence coverage and quality scores. Germline variants were excluded using remission samples and population variation.

Accessibility of Reported Variants
----------------------------------

All variants identified in the whole genome sequenced patients and the validation cohort are listed in the Supporting Information. Putative driver variants have been submitted to COSMIC with COSP ID 37259.

Further details on the materials and methods are available in the Supporting Information.

Results
=======

Somatic Variants in Whole Genome Sequenced ALL Patients
-------------------------------------------------------

In this study, four patients selected to be representative of pediatric ALL were subjected to WGS. ALL_458 (BCP-ALL) carried the recurrent t(12;21)(p13;q22)*ETV6-RUNX1* translocation, ALL_559 (T-ALL) had two translocations involving chromosome 7, ALL_707 (BCP-ALL) had several cytogenetic aberrations, including a t(7;9)(q11;p13) translocation, and ALL_501 (BCP-ALL) showed a normal karyotype (Table [1](#tbl1){ref-type="table"}). Each of the patients responded to treatment and had remained in first continuous complete remission (CCR1) for at least 5 years. We sequenced the genomes of diagnostic and remission samples from these patients to an average depth of 31× high quality aligned data and the transcriptomes from the diagnostic samples (Supp. [Table S5](#SD1){ref-type="supplementary-material"}).

In the genomes of the four patients, we identified between 713 and 851 candidate somatic SNVs and exonic insertion--deletions (indels) in non-repeated regions (Supp. [Table S6](#SD1){ref-type="supplementary-material"}). We validated close to 200 somatic SNVs and indels per BCP-ALL patient, and 305 in the T-ALL patient (Supp. [Tables S7--S8](#SD1){ref-type="supplementary-material"}) using PCR and Sanger sequencing and/or target capture and deep sequencing. A relatively low validation rate of 29% was obtained for SNVs (Supp. [Table S7](#SD1){ref-type="supplementary-material"}), which can be attributed to the non-stringent criteria for inclusion of candidate SNVs in the HaloPlex experiment. In addition, most comparable studies have focused on validation in exons, which are more conserved than the remaining part of the genome and less prone to alignment artifacts. Indeed, exonic SNVs were associated with both higher somatic scores, as defined by SomaticSniper, (averages of 87 and 72 for exonic and non-exonic candidates, respectively) and a substantially higher validation rate of 66% (Supp. [Table S7](#SD1){ref-type="supplementary-material"}). The candidate SNVs that failed to validate were either false positives, or had similar AFs in the leukemic and remission samples, suggesting that they were germline variants or alignment artifacts (Supp. [Fig. S3](#SD1){ref-type="supplementary-material"}). All further analysis includes only the validated variants. The validated SNVs were evenly distributed over the genome with no evidence of hypermutated regions (Fig. [1](#fig01){ref-type="fig"}A). The most common somatic mutation in all patients except ALL_707 (subtype "other") was C\>T, whereas C\>A was most frequent in ALL_707 (Fig. [1](#fig01){ref-type="fig"}B).

![**A**: Circos \[Krzywinski et al., [@b20]\] plots showing the genomic location of validated somatic single nucleotide variants (SNVs), insertion-deletions (indels), copy number alterations (CNAs), copy neutral loss of heterozygosity (LOH) events, and translocations in the whole genome sequenced ALL patients. SNVs and indels are shown as red (original clone) or blue (subclone) dots in the circle closest to the chromosomes. Inside the SNVs and indels, deletions are shown with red, duplications with blue and LOH with yellow circle segments. Black arcs indicate translocations. Gene names are color-coded as follows: gray, expressed genes with exonic indels or nsSNVs that were predicted to be damaging and genes that were highlighted as putative drivers in the validation cohort; black, genes involved in translocations; red, selected genes in CNA or LOH regions; green, selected differentially expressed genes that are located near breakpoints for translocations or putatively regulatory SNVs. **B**: Mutational patterns in the whole genome sequenced patients. The higher frequency of C\>A mutations compared to C\>T mutations in ALL_707 is significantly different from the other patients (chi-square test, *P* \< 0.001).](humu0036-0118-f1){#fig01}

We validated 23 exonic variants in the four patients, including three loss of function mutations, 18 nonsynonymous SNVs (nsSNVs), and two synonymous SNVs (Table [3](#tbl3){ref-type="table"}). Prediction of functional effects suggested that 11 out of 18 nsSNVs were damaging, including nsSNVs in *KRAS* (MIM\# 190070) and *NOTCH1* (MIM\# 190198), which are known drivers of BCP-ALL \[Liang et al., [@b26]\] and T-ALL \[Weng et al., [@b55]\], respectively. We validated 74 SNVs in non-coding putative regulatory regions, of which 50 were located in conserved regions, 16 in DNase hypersensitive (DHS) regions and eight had a high regulatory potential according to RegulomeDB (Supp. [Table S7](#SD1){ref-type="supplementary-material"} and Supp. [Fig. S4](#SD1){ref-type="supplementary-material"}). In comparison with the remaining non-coding SNVs, these putatively functional SNVs were more often located in introns and within 1 kb from a gene and less often in intergenic regions (Supp. [Fig. S4](#SD1){ref-type="supplementary-material"}).

###### 

Validated Exonic Single Nucleotide Variants and Insertion--Deletions in Whole Genome Sequenced ALL Patients

  Sample    Chr   Position    cDNA change[a](#tf3-1){ref-type="table-fn"}   Protein change   Gene      Gene description                                 Effect           SIFT[b](#tf3-2){ref-type="table-fn"}   PP2[c](#tf3-3){ref-type="table-fn"}   AF DNA[d](#tf3-4){ref-type="table-fn"}   AF RNA   FPKM sample   FPKM control[e](#tf3-5){ref-type="table-fn"}
  --------- ----- ----------- --------------------------------------------- ---------------- --------- ------------------------------------------------ ---------------- -------------------------------------- ------------------------------------- ---------------------------------------- -------- ------------- ----------------------------------------------
  ALL_458   2     178416648   c.844G\>A                                     p.E282K          TTC30B    Tetratricopeptide repeat domain 30B              nsSNV            D                                      D                                     0.12                                     0.14     2.2           0.8
  ALL_458   3     51749797    c.2008C\>T                                    p.R670W          GRM2      Glutamate receptor, metabotropic 2 isoform a     nsSNV            D                                      D                                     0.44                                     NA       0.1           0.1
  ALL_458   12    11285961    c.883C\>T                                     p.R295W          TAS2R30   Type 2 taste receptor member 30                  nsSNV            T                                      B                                     0.33                                     0.00     0.2           1.6
  ALL_559   1     10363472    c.2229T\>G                                    p.I743M          KIF1B     Kinesin family member 1B isoform b               nsSNV            D                                      D                                     0.34                                     0.20     2.5           3.3
  ALL_559   1     11186751    c.1069C\>T                                    p.R357C          MTOR      FK506 binding protein 12-rapamycin associated    nsSNV            T                                      B                                     0.56                                     0.60     12.3          10.8
  ALL_559   1     32745467    c.1067A\>C                                    p.E356A          LCK       Lymphocyte-specific protein tyrosine kinase      nsSNV            D                                      D                                     0.61                                     0.64     306.8         67.2
  ALL_559   3     48617469    c.5119C\>T                                    p.R1707W         COL7A1    Alpha 1 type VII collagen precursor              nsSNV            D                                      P                                     0.47                                     1.00     0.0           0.3
  ALL_559   5     180053029   c.1261C\>T                                    p.P421S          FLT4      fms-related tyrosine kinase 4 isoform 2          nsSNV            D                                      P                                     0.35                                     NA       0.0           1.0
  ALL_559   6     39864708    c.2462G\>A                                    p.R821Q          DAAM2     Dishevelled associated activator of              nsSNV            T                                      P                                     0.40                                     0.00     0.1           1.6
  ALL_559   6     84055977    c.515G\>T                                     p.G172V          ME1       Cytosolic malic enzyme 1                         nsSNV            D                                      D                                     0.39                                     0.00     0.1           0.0
  ALL_559   9     139397768   c.5033T\>C                                    p.L1678P         NOTCH1    Notch1 preproprotein                             nsSNV            D                                      D                                     0.31                                     0.29     9.5           7.8
  ALL_559   15    41165511    c.456C\>T                                     p.N152N          RHOV      ras homolog gene family, member V                sSNV             NA                                     NA                                    0.22                                     NA       0.1           0.1
  ALL_559   17    4536237     c.1459G\>A                                    p.V487M          ALOX15    Arachidonate 15-lipoxygenase                     nsSNV            D                                      P                                     0.45                                     NA       0.0           0.0
  ALL_559   19    13041102    c.438_439insG                                 p.G146fs         FARSA     Phenylalanyl-tRNA synthetase, alpha subunit      frameshift ins   NA                                     NA                                    0.62                                     0.36     8.8           9.5
  ALL_707   12    25398281    c.38G\>A                                      p.G13D           KRAS      c-K-ras2 protein isoform a precursor             nsSNV            D                                      NA                                    0.38                                     0.25     14.5          10.9
  ALL_707   20    10030811    c.1594G\>T                                    p.A532S          ANKEF1    Ankyrin repeat and EF-hand domain containing 1   nsSNV            D                                      D                                     0.39                                     NA       0.1           0.2
  ALL_707   21    42609582    c.544G\>T                                     p.E182X          BACE2     Beta-site APP-cleaving enzyme 2 isoform A        nonsense SNV     NA                                     NA                                    0.41                                     0.00     NA            NA
  ALL_501   X     151092993   c.857A\>G                                     p.K286R          MAGEA4    Melanoma antigen family A, 4                     nsSNV            T                                      P                                     0.32                                     NA       0.0           0.0
  ALL_501   X     48382171    c.12C\>T                                      p.N4N            EBP       Emopamil binding protein (sterol isomerase)      sSNV             NA                                     NA                                    0.46                                     0.00     30.4          16.0
  ALL_501   1     157659674   c.1724C\>T                                    p.A575V          FCRL3     Fc receptor-like 3 precursor                     nsSNV            T                                      B                                     0.31                                     0.00     0.6           0.7
  ALL_501   2     61711139    c.2610G\>C                                    p.Q870H          XPO1      exportin 1                                       nsSNV            T                                      B                                     0.46                                     0.48     115.1         107.1
  ALL_501   11    112123109   c.410C\>T                                     p.A137V          PLET1     Hypothetical protein LOC349633 precursor         nsSNV            T                                      B                                     0.38                                     0.00     0.2           0.2
  ALL_501   12    49426841    c.11647_11648insGCTC                          p.H3883fs        KMT2D     Lysine (K)-specific methyltransferase 2D         frameshift ins   NA                                     NA                                    0.60                                     0.32     5.2           15.4

Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.

SIFT predictions: D, damaging; T, tolerated.

PolyPhen2 (PP2) predictions: D, probably damaging; P, possibly damaging; B, benign.

AF from deep-sequencing data. The AF for the SNV in *TAS2R30* is from WGS data, as this SNV was not covered in the deep-sequencing data.

The shown expression value represents the mean of 27 BCP-ALL (for ALL_458, ALL_707 and ALL_501) or 18 T-ALL (for ALL_559) samples.

Chr, chromosome; nsSNV, nonsynonymous SNV; sSNV, synonymous SNV; ins, insertion; AF, allele fraction; FPKM: fragments per kilobase of transcript per million mapped reads.

Using a combination of the WGS data and high-density genotype data, we identified between two and five somatic CNAs and copy-neutral loss of heterozygosity (LOH) events in the four patients (Fig. [1](#fig01){ref-type="fig"}A and Table [4](#tbl4){ref-type="table"}). The majority of the events (10/15) were not detected by cytogenetic analysis at diagnosis. The portion of the genome affected by these events varied between 428 kb in ALL_501 (normal karyotype) and 176 Mb in ALL_458 (t(12;21)). Several of the aberrations, including deletions of the wild type *ETV6* \[12p13\] and *VPREB1* (MIM\# 605141) \[22q11\] in ALL_458, *CDKN2A* (MIM\# 600160) \[9p21\] in ALL_559 (T-ALL) and ALL_707 (subtype "other"), and *IKZF1* (MIM\# 603023) \[7p12\] in ALL_501, and duplication of chromosome 10 in ALL_458, are known to be recurrent in pediatric ALL \[Mullighan et al., [@b38]; Lilljebjorn et al., [@b28]; Mangum et al., [@b30]\]. Both of the *CDKN2A* deletions were homozygous and they were flanked by two LOH events in ALL_559 and by two hemizygous deletions in ALL_707. Other deletions include, for example, the oncogenes *MDM2* (MIM\# 164785) and *RAP1B* (MIM\# 179530) in ALL_458 and the putative tumor suppressors *FOXP1* (MIM\# 605515), *RYBP* (MIM\# 607535), and *SHQ1* (MIM\# 613663) in ALL_559 (Table [4](#tbl4){ref-type="table"}).

###### 

Somatic Copy Number Alterations in Whole Genome Sequenced ALL Patients

  Sample    Subtype    Chr   Start      End         Size (kb)[a](#tf4-1){ref-type="table-fn"}   Type[b](#tf4-2){ref-type="table-fn"}   Cytoband      Cytogenetic prediction[c](#tf4-3){ref-type="table-fn"}   Affected genes                         FPKM sample[d](#tf4-4){ref-type="table-fn"}   FPKM control[e](#tf4-5){ref-type="table-fn"}
  --------- ---------- ----- ---------- ----------- ------------------------------------------- -------------------------------------- ------------- -------------------------------------------------------- -------------------------------------- --------------------------------------------- ----------------------------------------------
  ALL_458   t(12;21)   10    1          135534747   135,535                                     Dup\*                                  all chr 10    NA                                                       691 genes                              21.9                                          13.3
  ALL_458   t(12;21)   11    96600814   134944379   38,344                                      Del\*                                  q21-q25       NA                                                       261 genes                              11                                            10.6
  ALL_458   t(12;21)   12    11253986   13357791    2,104                                       Del                                    p13.2-p13.1   p13                                                      25 genes including ETV6                3.1                                           6.5
  ALL_458   t(12;21)   12    68835364   69203100    368                                         Del                                    q15           NA                                                       MDM2, NUP107, RAP1B, SLC35E3           85.4                                          87.6
  ALL_458   t(12;21)   22    22569501   22600200    31                                          Del                                    q11.22        NA                                                       VPREB1                                 39.3                                          72.3
  ALL_559   T-ALL      3     70233601   74494601    4,261                                       Del                                    p13-p12.3     NA                                                       11 genes including FOXP1, RYBP, SHQ1   6                                             9.8
  ALL_559   T-ALL      9     46587      21295942    21,249                                      LOH                                    p24.3-p21.3   NA                                                       74 genes                               46.5                                          28.5
  ALL_559   T-ALL      9     21300000   22100401    800                                         Del                                    p21.3         p21×2                                                    11 genes including CDKN2A, CDKN2B      0.1                                           0.9
  ALL_559   T-ALL      9     22110997   32243981    10,133                                      LOH                                    p21.3-p21.1   NA                                                       13 genes                               1.5                                           1.5
  ALL_707   Other      9     197421     21980801    21,783                                      Del                                    p24.3-p21.3   p21-p24                                                  82 genes                               25.7                                          19.9
  ALL_707   Other      9     21980802   22021001    40                                          Del                                    p21.3         p21-p24                                                  CDKN2A, CDKN2B                         0                                             1.2
  ALL_707   Other      9     22021002   36908001    14,887                                      Del                                    p21.3-p13.2   p21-p24                                                  92 genes                               28.3                                          34.9
  ALL_707   Other      19    58519186   59089786    571                                         Del                                    q13.43        q13                                                      23 genes                               18.9                                          16.8
  ALL_501   Normal     2     89165816   89554016    388                                         Del                                    p11.2         NA                                                       NA                                     NA                                            NA
  ALL_501   Normal     7     50412894   50463634    51                                          Del                                    p12.2         NA                                                       IKZF1                                  84.6                                          71.1

The size represents the minimal overlap between different predictions. The breakpoints of the *IKZF1* deletion were determined by analysis of softclipped reads in the WGS data.

A \* indicates that the CNA is subclonal.

Results of cytogenetic analysis at diagnosis. NA indicates that no aberration was observed in the region by cytogenetic analysis.

Mean expression of genes located within the CNA in the sample harboring the CNA.

Mean expression of genes located within the CNA in the control data set, where each gene is represented by the mean of 27 BCP-ALL (for ALL_458, ALL_707 and ALL_501) or 18 T-ALL (for ALL_559) samples.

Chr, chromosome; Dup, duplication; Del, deletion; LOH, loss of heterozygosity; FPKM, fragments per kilobase of transcript per million mapped reads; CNA, copy number alteration.

Allele Fractions of Somatic Variants Reveal Clonal Heterogeneity
----------------------------------------------------------------

As we have shown before, target capture followed by deep sequencing allows accurate estimation of the AF of somatic SNVs and enables detection of clonal heterogeneity \[Berglund et al., [@b4]\]. Analysis of the validated somatic SNVs revealed a large density peak with AF 0.41--0.46 in each of the four whole genome sequenced patients (Fig. [2](#fig02){ref-type="fig"}A), in agreement with the estimation that the samples contained 80%--95% leukemic blasts. In addition, density peaks indicative of subclones with AF of 0.19 and 0.27, were observed in ALL_458 (t(12;21)) and ALL_559 (T-ALL), respectively. Based on the AFs, we estimate that approximately half of the SNVs in ALL_458 belong to the subclone, and that 40% of the leukemic cells carry these SNVs. For comparison, an SNV present in the original clone is expected to be present in all leukemic cells, including those that belong to the subclone. The subclone in ALL_559 contains fewer (30%) of the SNVs, but they are present in a larger proportion (60%) of the leukemic cells. Comparison of the mutational patterns of the SNVs that were present in the original clones and those arising in the subclones showed no major differences, although the subclones contained a larger proportion of C\>T substitutions than the original clone in both patients (Fig. [2](#fig02){ref-type="fig"}B). ALL_707 and ALL_501 did not display additional density peaks, however, both patients harbored a substantial number of SNVs with relatively low AF, which could indicate the presence of minor clones with few SNVs. It should also be noted that because of the limited sequence depth in the WGS data, only subclones present in a relatively large proportion of the cells would have been detected.

![**A**: Density plot showing the allele fraction (AF) distribution of validated somatic single nucleotide variants (SNVs) in the four whole genome sequenced ALL patients. Each sample displays a density peak with AF between 0.41 and 0.46. In addition, ALL_458 and ALL_559 display density peaks with AF of 0.19 and 0.27, respectively, indicative of subclones. **B**: Mutational patterns of SNVs belonging to the original clone and the subclone for ALL_458 and ALL_559. **C**: Subclonal copy number alterations (CNAs) in ALL_458 visualized using Omni2.5 BeadChip data. The top panel shows the log *R* ratio (LRR) and the bottom panel shows the B-allele frequency (BAF) for the duplication of chromosome 10 (left) and the deletion of chromosome 11q21--25 (right). R corresponds to the total intensity of each probe, and LRR is the log~2~ of the ratio of the measured normalized *R*-value in the ALL sample and the normalized *R*-value of the reference. LRR = 0 indicates no change in copy number. BAF represents the AF, with values of 0 and 1 indicating homozygosity and 0.5 indicating heterozygosity in a diploid genomic region. The solid and dashed lines correspond to the estimated BAF if the CNA is present in 40% and 100% of the leukemic cells, respectively. The red dots show the genomic location of somatic SNVs, with the position on the *y*-axis corresponding to the AF.](humu0036-0118-f2){#fig02}

Analysis of the AF of SNPs from genotyping data suggested that the duplication of chromosome 10 and the deletion of chromosome 11q21--25 in ALL_458 were subclonal (Fig. [2](#fig02){ref-type="fig"}C). Interestingly, the somatic SNVs on chromosome 10 fell into three AF clusters, which provide clues to when and where these mutations occurred. The first cluster (*n* = 3 SNVs) showed low AF (0.10--0.13), suggesting that these SNVs occurred in the subclone, either before duplication on the non-duplicated allele or after duplication on any allele. The second cluster of SNVs (*n* = 3, AF 0.32--0.36) likely occurred on the non-duplicated allele in the original clone. The third set of SNVs (*n* = 2) had high AF (0.52--0.55), and probably occurred in the original clone, on the allele that was subsequently duplicated in the subclone. The SNVs in the deleted region on chromosome 11 also have varying AFs, however, the low number of SNVs (*n* = 3) hinders inference of their origin.

Expression of Genes Affected by Somatic Variants
------------------------------------------------

Using RNA-seq data, we found that 10 of the 23 genes with validated somatic exonic variants were expressed at ≥ 1 fragment per kilobase of transcript per million mapped reads (FPKM) (Table [3](#tbl3){ref-type="table"}). The variant allele was expressed in 9/10 genes, but never overexpressed in comparison to the AF in DNA (Table [3](#tbl3){ref-type="table"}). To assess the putative effect of the somatic variants on gene expression, we compared to immunophenotype-matched control RNA-seq datasets, consisting of 27 BCP-ALL samples or 18 T-ALL samples (Supp. [Table S2](#SD1){ref-type="supplementary-material"}). In comparison with the control dataset, *LCK* (MIM\# 153390) was 4.6-fold overexpressed and *KMT2D* (MIM\# 602113, previously named *MLL2*) was threefold underexpressed in the samples harboring the variants (Table [3](#tbl3){ref-type="table"}). Of the 14 genes with damaging or loss of function mutations, 50% (*n* = 7) were expressed, in comparison with 33% (3/9) of the genes with predicted benign variants. We also observed at least 1.6-fold decreased expression of the genes in three of the nine hemizygous deletions that affected at least one gene, almost complete loss of expression in the two homozygous deletions, and 1.6-fold increased expression of the genes on the duplicated chromosome 10 (Table [4](#tbl4){ref-type="table"}). The expression of the genes on chromosome 9p24--21 with copy-neutral LOH was 1.6-fold increased in ALL_559 compared with the control dataset, whereas there was no difference in expression of the genes in the other LOH region on the same chromosome (Table [4](#tbl4){ref-type="table"}).

Next, we analyzed putative effects of non-coding SNVs on the expression of nearby genes. A total of 125 SNVs that were located in a conserved or DHS region, had a RegulomeDB score ≤ 4, or a score from FunSeq \[Khurana et al., [@b17]\] ≥ 3, were included in the analysis. In order to call a gene differentially expressed, we required a fourfold relative difference and an absolute difference of at least 3 standard deviations between the sample and the control. Using these criteria, we identified 31 genes that were differentially expressed in comparison to the control dataset, all of which were overexpressed, corresponding to 19 putatively regulatory SNVs (Supp. [Table S9](#SD1){ref-type="supplementary-material"}). These 19 SNVs were located in introns (*n* = 8), intergenic regions (*n* = 8) or the 5′ flank of a gene (*n* = 3). Three of the intronic SNVs were covered by at least two reads in the RNA-seq data, putatively representing unspliced mRNAs (Supp. [Table S9](#SD1){ref-type="supplementary-material"}). To further investigate the putative function of these variants, we determined the overlap between SNVs and known histone marks in lymphoid cells (Supp. [Table S9](#SD1){ref-type="supplementary-material"}). Eight of the 19 putative regulatory SNVs, associated with differential expression of 12 genes, overlapped with histone marks. Notably, an SNV located 53 kb upstream of the growth factor *MDK* (MIM\# 162096), which was overexpressed in ALL_458 (t(12;21)) overlapped with markers for enhancer elements (H3K27ac and H3K4me1 modifications) and active transcription (H3K4me3 modification).

We also used the RNA-seq data to identify expressed fusion genes (Supp. [Table S10](#SD1){ref-type="supplementary-material"}). In addition to the canonical *ETV6-RUNX1* fusion in ALL_458, which was detected by RT-PCR at diagnosis, the RNA-seq data revealed expression of the reciprocal fusion gene *RUNX1-ETV6* that contains the first exon of *RUNX1* and the last three exons of *ETV6*. Cytogenetic analysis of ALL_559 (T-ALL) detected the two translocations t(7;9) and t(7;11). RNA-seq demonstrated that both translocations result in expressed fusion genes with a common 3′ partner *TRBC2* (MIM\# 615445), which is part of the T-cell receptor beta locus \[7q34\]. The 5′ partners were *RIC3* (MIM\# 610509) \[11p15\] and a non-annotated gene located 500 bp upstream of *TMEM38B* (MIM\# 611236) \[9q31\]. We observed overexpression of *LMO1* (MIM\# 186921) and *TUB* (MIM\# 601197), which flank *RIC3*, and *TAL2* (MIM\# 186855), which is located downstream of *TMEM38B*, in ALL_559 compared with other T-ALL samples (Fig. [3](#fig03){ref-type="fig"}). ALL_707 also had a t(7;9) based on karyotype data. RNA-seq demonstrated that this fusion resulted in a highly expressed *PAX5-ELN* (MIM\#s 167414, 130161) fusion gene (Fig. [3](#fig03){ref-type="fig"}). We did not detect any expressed fusion genes apart from those resulting from the translocations detected at diagnosis in the three patients mentioned above and no fusions were detected in ALL_501 with normal karyotype.

![Bar plots showing the expression of five genes up- and downstream of genes involved in chromosomal rearrangements. The gene involved in the fusion, if annotated, is highlighted in bold. Genes exhibiting a fourfold relative difference and an absolute difference of at least 3 standard deviations between the sample and the control are marked with a \*. **A and B:** Expression changes in ALL_559 associated with the fusions of *TRBC2* with *RIC3* (**A**) and a non-annotated gene close to *TMEM38B* (**B**). *LMO1*, *TUB*, and *TAL2* are overexpressed in ALL_559 compared with 18 T-ALL samples. **C and D:** Expression changes in ALL_707 associated with the *PAX5-ELN* fusion. *ELN*, which constitutes the major part of the fusion gene, is overexpressed in ALL_707 compared with 27 BCP-ALL samples suggesting that the *PAX5-ELN* fusion gene is highly expressed.](humu0036-0118-f3){#fig03}

Recurrently Mutated Genes and Regions Identified by Targeted Sequencing
-----------------------------------------------------------------------

To ascertain if any of the genes or putative regulatory regions identified by WGS of four patients were recurrently mutated in ALL, we performed target capture and deep sequencing of these regions in a cohort of 145 BCP-ALL and 23 T-ALL samples (Table [2](#tbl2){ref-type="table"} and Supp. [Tables S1 and S4](#SD1){ref-type="supplementary-material"}). Matched DNA from remission was sequenced in pools for 159 of the patients, and analysis of the sequence data demonstrated that 139 of the remission samples were well represented in the pools and could be used to filter out germline variants (Supp. Methods). In these 139 patients, we detected on average 0.7 SNVs, whereas in the remaining 29 patients, we detected on average 3.0 SNVs. This result suggests that the majority of the SNVs called in the samples without matched remission sample are germline variants. To avoid false positives we only report variants included in the COSMIC database for these samples.

We detected 107 SNVs (Supp. [Table S11](#SD1){ref-type="supplementary-material"}) and 15 indels (Supp. [Table S12](#SD1){ref-type="supplementary-material"}) in the validation cohort, including 43 SNVs and 10 indels in exons or UTRs of the 30 resequenced genes (Fig. [4](#fig04){ref-type="fig"}). The most frequently mutated genes were *KRAS* (18 SNVs affecting 16 patients) and *NOTCH1* (9 SNVs and 7 indels, affecting 12 patients). 17/18 *KRAS* mutations were found in BCP-ALL patients, and all *NOTCH1* mutations were found in T-ALL patients. In addition to *KRAS* and *NOTCH1*, we identified *KMT2D*, *KIF1B* (MIM\# 605995) and *ME1* (MIM\# 154250) as novel putative driver genes using three complementary tools (MutSigCV, Lawrence et al. ([@b23]) Oncodrive-fm, Gonzalez-Perez, Lopez-Bigas ([@b10]) and OncodriveCLUST, Tamborero et al. ([@b47])). To find subtype-specific patterns, we analyzed the T-ALL samples and the largest BCP-ALL subtypes (HeH, t(12;21), normal and other) individually. *KRAS* was highlighted as driver in all BCP-ALL subtypes except t(12;21) and *NOTCH1* was highlighted in T-ALL. No subtype-specific pattern was observed for the novel genes.

![Recurrent somatic mutations detected in the validation cohort in the genes that were identified by WGS. Each column represents one patient, with the whole genome sequenced samples in the four leftmost columns. In the upper panel, each row represents one gene. Only samples and genes with at least one mutation in an exon, splice site, or untranslated region (UTR) in the validation cohort are shown. Each colored box indicates a mutation. For patients with more than one variant in the same gene, the color is prioritized according to the order shown in the legend. In the lower panel, the genetic subtype of each sample is shown.](humu0036-0118-f4){#fig04}

Recurrent mutations in UTRs were identified in several genes (Fig. [4](#fig04){ref-type="fig"}), however, the mutations were co-located in either the 3′ or the 5′ UTR only for *ASTN1* (MIM\# 600904), which is not expressed in ALL according to our RNA-seq dataset. For identification of recurrently mutated non-coding regions in the validation cohort, we defined "super-regions" consisting of all non-coding regions that were selected because of the same original SNV (Supp. Methods). In most cases, the super-regions consisted of a contiguous genomic region, however, in cases where the SNV was located in a conserved region, they contained all conserved regions within 2 kb. Twelve non-coding super-regions were found to harbor recurrent mutations in the validation cohort (Supp. [Table S13](#SD1){ref-type="supplementary-material"}). The original SNVs detected by WGS were located in a conserved (*n* = 4) or DHS region (*n* = 1), had a RegulomeDB hit (*n* = 1), were located in a DHS region and had a RegulomeDB hit (*n* = 1), or lacked functional annotation (*n* = 5). Two SNVs overlapped histone marks for enhancer elements (H3K27ac and H3K4me1) and active transcription (H3K4me3). One specific SNV (chr4:157006979C\>T) was identified in two t(12;21) patients, including the whole genome sequenced ALL_458. This SNV did not overlap any of the annotated regions or histone marks, and the possible functional implications are unclear.

Discussion
==========

In this study, we performed a thorough characterization of the genomes of four representative pediatric ALL patients using WGS and RNA-seq. We validated and determined the AFs of somatic variants genome-wide and identified recurrently mutated coding and non-coding regions by targeted sequencing of 168 additional ALL patients.

In ALL_458 (t(12;21)), we found deletions of *ETV6* and *VPREB1*, in line with previous observations that patients with the *ETV6-RUNX1* translocation often harbor deletions that target genes involved in B-cell development \[Mullighan et al., [@b38]; Papaemmanuil et al., [@b40]\]. We also observed expression of the rarely reported reciprocal *RUNX1-ETV6* fusion gene, which has been suggested to be involved in cellular regrowth \[Stams et al., [@b46]; Al-Shehhi et al., [@b1]\], and overexpression of *MDK* coinciding with a putative regulatory SNV located in an enhancer element and DHS region 53 kb upstream of the gene. *MDK* is involved in cancer development and has previously been shown to be upregulated in BCP-ALL compared to normal peripheral blood and bone marrow \[Hidaka et al., [@b13]\]. ALL_458 also contained a subclone with a large number of SNVs, suggesting that these cells have an increased mutation rate and/or a growth advantage during leukemic progression compared to the cells in the original clone. Clonal heterogeneity has previously been observed in ALL by copy number profiling \[Jan and Majeti, [@b15]\] or analysis of AFs from exome sequencing \[Papaemmanuil et al., [@b40]\] and is one of the most important challenges for the successful application of targeted therapies \[Landau et al., [@b21]\]. Despite the potentially rapidly growing subclone and the presence of two lesions that have been suggested to have a negative impact on clinical outcome, namely the deletion of *VPREB* \[Mangum et al., [@b30]\] and the expression of *RUNX1-ETV6* \[Stams et al., [@b46]\], this patient responded well to treatment and has remained in CCR1. The absence of SNVs or indels in putative driver genes in ALL_458, the few *KRAS* mutations in t(12;21) patients, and the previous failure to identify recurrently mutated genes by exome sequencing of t(12;21) patients \[Lilljebjorn et al., [@b27]\] suggest that point mutation in exons of protein-coding genes is not a dominant force for leukemic development in this subtype.

We identified several lesions that are characteristic of T-ALL in ALL_559, including a *NOTCH1* mutation, two translocations involving the T-cell receptor beta locus \[Le Noir et al., [@b24]\] that resulted in overexpression of *LMO1* \[Atak et al., [@b3]\] and *TAL2* \[Marculescu et al., [@b31]\], and deletion of the tumor suppressor *CDKN2A* \[Mullighan et al., [@b38]\]. ALL_559 also displayed mutation and overexpression of the proto-oncogene *LC[k]{.smallcaps}*, which is involved in T-cell development. *LCK* has previously been found to be mutated and overexpressed in fusions with the T-cell receptor region in T-ALL and it was suggested that oncogenic transformation of *LCK* requires two mutations, one that deregulates gene transcription and one that activates protein function \[Wright et al., [@b59]\]. Although we did not identify any regulatory SNV that could cause the aberrant expression of *LCK* in ALL_559, it is possible that there is a regulatory SNV that is located at a larger distance than 1 Mb from *LCK* or that another type of genetic lesion is involved. Findings in our study that are novel in T-ALL include deletion of the putative tumor suppressors *FOXP1, RYBP* and *SHQ1*, which has frequently been observed in prostate cancer and has been suggested to exert a tumor-promoting effect \[Krohn et al., [@b19]\], the novel fusion partner for *TRBC2* in a non-annotated gene on 9q31, and the identification of *ME1* and *KIF1B* as putative driver genes. Although *ME1* is not expressed in any of the T-ALL samples in our RNA-seq dataset and probably does not play a major role in leukemogenesis, *KIF1B* is expressed and has been suggested to be a tumor suppressor that contributes to cancer development by dosage reduction \[Henrich et al., [@b12]\].

Recurrent lesions in ALL_707 (subtype "other") included the *KRAS* mutation \[Liang et al., [@b26]\], the *CDKN2A* deletion \[Mullighan et al., [@b38]\], and the *PAX5-ELN* fusion gene \[Bousquet et al., [@b7]\]. We did not identify any novel putative driver events in this patient, however, we observed a large number of C\>A mutations, in contrast to the other patients where the dominant mutation was C\>T. Although C\>T mutations are common in most cancer types, and can be caused by UV-light or deamination of 5-methylcytosines \[Alexandrov et al., [@b2]\], excessive C\>A mutations have mainly been observed in lung cancer, and have been attributed to tobacco exposure \[Pleasance et al., [@b41]\]. Future studies will reveal whether this mutational signature, which has not previously been observed in ALL, will be detected in other ALL patients.

ALL_501 was selected for this study because its karyotype was completely normal, and we were especially interested in finding the driver events in this patient. In agreement with the cytogenetic results, we found no fusion gene or large CNA. We detected a focal deletion of exons 3--6 in *IKZF1*, which encodes the transcription factor Ikaros that plays key roles in lymphoid development and tumor suppression. The resulting transcript, which lacks four zinc fingers that are required for DNA binding and therefore is unable to bind transcriptional targets, is known as Ik6 and acts as a dominant negative inhibitor of Ikaros function \[Mullighan and Downing, [@b36]\]. The second finding in ALL_501 was a frameshift insertion and reduced expression of *KMT2D* (*MLL2*), which was highlighted as a putative driver gene in the validation cohort. Frequent loss-of-function mutations in *KMT2D*, which encodes a histone methyltransferase involved in regulation of gene transcription, have been found in a range of cancers, and this gene has been proposed to be a tumor suppressor and a putative therapeutic target \[Guo et al., [@b11]\]. An intriguing question is whether these two mutations are sufficient to induce leukemia. Mouse models have shown that expression of Ik6 can induce T-cell leukemia \[Winandy et al., [@b57]\], however, expression exclusively in B-cells does not result in B-lineage leukemia \[Wojcik et al., [@b58]\]. Point mutations in *KMT2D* have, to our knowledge, not been reported as putative drivers before in ALL, and their role in leukemogenesis is yet to be determined.

In summary, we provide a high-resolution map of the genomes of four representative pediatric ALL patients. We found that each patient had a unique genome, with a combination of well known and previously undetected genomic aberrations, including SNVs, CNAs, and chromosomal rearrangements. Despite the limited size of the discovery cohort we identified *KMT2D* and *KIF1B* as novel putative driver genes in ALL, which suggests that analysis of more samples would enable identification of additional genes. The non-annotated fusion partner to *TRBC2* is an example of a novel finding enabled by RNA-seq. Our finding that overexpression of *MDK* coincide with a non-coding putative regulatory SNV suggests that regulatory variants may be more important for the development of ALL and other cancers than recognized to date, and that future WGS and RNA-seq studies in larger cohorts combined with functional experiments will be useful to explore this area. The results from our study as well as earlier sequencing studies \[Roberts et al., [@b43]; Zhang et al., [@b61]; Holmfeldt et al., [@b14]; Papaemmanuil et al., [@b40]\] contribute to an increased understanding of the biological mechanisms that lead to ALL. The heterogeneity of the genetic aberrations in ALL, and lack of large numbers of recurrent mutations renders WGS particularly well suited for diagnosis and stratification of ALL patients into subgroups for new treatment protocols. Analysis of serially collected samples from the 20% of patients that relapse has already revealed mechanisms of clonal evolution that provide clues to the cause of treatment failure \[Meyer et al., [@b35]; Tzoneva et al., [@b51]\], and more extensive studies are likely to further increase the understanding of the biology behind relapse in ALL. Next generation sequencing technology has developed fast in recent years, and today it is a reality to apply WGS at costs and speed that are acceptable for routine clinical genetic diagnostics of ALL.
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